Aethlon Medical, Inc. announced on November 11, 2024, the enrollment of the first patient in its Australian safety, feasibility, and dose-finding clinical trial of the Hemopurifier. The patient was enrolled on October 29, 2024, at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital in Australia.
This trial focuses on patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment. The patient completed screening on November 8, 2024, and entered a two-month run-in period to assess response to anti-PD-1 therapy.
The primary endpoint of this nine to 18-patient study is safety, with exploratory analyses to examine the reduction of extracellular vesicles (EVs) and improvements in anti-tumor T-cell activity. This milestone is expected to inform the design of subsequent efficacy and safety trials.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.